Trials / Completed
CompletedNCT02870400
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to assess the safety and tolerability of single ascending doses of REGN2477 in healthy women not of childbearing potential.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2477 | Participants will receive ascending doses of REGN2477 |
| DRUG | Placebo | Participants will receive matching placebo |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-01-12
- Completion
- 2017-01-12
- First posted
- 2016-08-17
- Last updated
- 2017-02-20
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02870400. Inclusion in this directory is not an endorsement.